MARKET WIRETradingView • 10h ago
Genenta Science S.p.A. Estimates – NASDAQ:GNTATradingView report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
Why GNTA Stock slipped -0.27% Today — RQD Quant Desk Flash
$0.62 -0.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.62
Genenta Science S.p.A. (GNTA) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $29.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on GNTA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is GNTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Genenta Science S.p.A. (NASDAQ: GNTA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.62 (-0.27% 1D, market cap $29.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GNTA ranks #302 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does GNTA compare to MGX and ALGS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GNTA carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MGX (Metagenomi Therapeutics Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ALGS (Aligos Therapeutics Inc.) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M). Among the 5-stock peer group, GNTA leads on earnings multiple (N/A) while MGX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for GNTA?
▼
For Genenta Science S.p.A. (GNTA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #302 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.62 (-0.24%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-3.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GNTA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY GNTA SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)
SEC XBRL Trailing 12 Months: 0% FCF Margin ($837.0K FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$0.76-13.2% Next Q
58
Q2 (-2Q)Grade C$0.66-6.1% Next Q
55
Q3 (-1Q)Grade C-$0.62+0% Next Q
53
CurrentGrade D$0.62-1.4% Hist 90D α
50
Trajectory: C (58) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a GNTA Turnaround Squeeze
While GNTA currently carries a cautious 50/100 (D) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.78) and Max Pain ($0.65) forces dealer call-delta covering toward $3.08.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GNTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GNTA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GNTA Stock slipped -0.27% Today — RQD Quant Desk Flash
Genenta Science S.p.A. (GNTA) slipped -0.27% to $0.62, trading at 3% of its 52-week range ($0.55 – $2.93). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($0.55 – $2.93) with RSI-14 at 36.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.62 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $837045 annual free cash flow.
Live GNTA Headlines & Catalysts
MARKET WIREStock Titan • 13h ago
Shareholders need no action as Genenta adopts the Saentra Forge nameStock Titan report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 16h ago
Genenta Science receives Nasdaq minimum bid price deficiency noticeTradingView report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 19h ago
A new business name, not a legal-name change: Genenta Science (Nasdaq: GNTA) will use Saentra Forge.Stock Titan report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Manila Times • 22h ago
Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency NotificationThe Manila Times report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Genenta Science S.p.A. ADR (GNTA) Stock Price Prediction for 2026, 2030-2040Traders Union report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Genenta Science S.p.A. ADR Stock Price Today | GNTA Live Chart & NewsTraders Union report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETipRanks • 1d ago
Genenta Science Faces Nasdaq Minimum Bid Price Deficiency, Explores Options to Preserve ListingTipRanks report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 13h ago
Genenta Unveils Saentra Forge as Its New Brand, Advancing Its Transformation into a Strategic Industrial PlatformNasdaq Ticker to Change to ‘SAEN’ on November 4, 2026MILAN, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) (the “Company”) today announced that it will do business as Saentra Forge and that its A
MARKET WIREBenzinga • 17h ago
Genenta Science Will Do Business As Saentra Forge, With Its ADSs Trading On The Nasdaq Capital Market Under New Ticker Symbol 'SAEN,' Effective November 4On October 20, 2026, the Board of Directors resolved that the Company will do business as Saentra Forge and approved the change of the ticker symbol of its ADSs from "GNTA" to "SAEN."The new identity
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GNTA)
- ✓Walkthrough of GNTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GNTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.14%▲ RESISTANCE BREAKOUT
2026-11-02O $0.60H $0.62L $0.60C $0.62VOL 153.2K
RES: $0.48SUP: $0.30SMA50: $0.78SMA200: $1.03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GNTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GNTA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GNTA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GNTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GNTA)
Health Care Rank #302 of 1016
⚔️ MGX vs GNTA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GNTA vs. MGX, ALGS, ESLA, EVAX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Genenta Science S.p.A. (GNTA) ranks #302 by composite RQD confidence (50/100, grade D) and #804 by equity capitalization ($29.9M). Within this direct 5-issuer industry benchmark cohort, GNTA leads on earnings valuation at N/A trailing P/E, while MGX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GNTA
ACTIVE
Genenta Science S.p.A. | D | 50/100 | — | — | — | -0.27% | $29.9M | Benchmark Subject |
| MGX Metagenomi Therapeutics Inc. | E | 24/100 | — | — | -35.0% | -6.01% | $31.4M | /mgx-vs-gnta → |
| ALGS Aligos Therapeutics Inc. | E | 22/100 | — | — | -35.0% | -4.57% | $31.4M | /algs-vs-gnta → |
| ESLA Estrella Immunopharma Inc. | D- | 39/100 | — | — | -35.0% | -12.27% | $31.7M | /esla-vs-gnta → |
| EVAX Evaxion A/S | D | 48/100 | — | — | — | -4.87% | $27.8M | /evax-vs-gnta → |
2. GNTA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTGenenta Science S.p.A. (GNTA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $29.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. GNTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GNTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Genenta Science S.p.A. (NASDAQ: GNTA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.62 (-0.27% 1D, market cap $29.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GNTA ranks #302 in composite RQD confidence.
How does GNTA compare to MGX and ALGS in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GNTA carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MGX (Metagenomi Therapeutics Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ALGS (Aligos Therapeutics Inc.) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M). Among the 5-stock peer group, GNTA leads on earnings multiple (N/A) while MGX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GNTA?
For Genenta Science S.p.A. (GNTA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #302 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GNTA trading relative to its 50-day, 200-day, and 52-week technical levels?
GNTA last traded at $0.62 (-0.27% on volume of 67,198 shares), positioning the stock -20.51% below its 50-day simple moving average ($0.78) and -39.81% below its 200-day simple moving average ($1.03). Across its 52-week range of $0.55 to $2.93, GNTA sits at the 2.9% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.70).
GNTA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GNTA stock moving today?
Why GNTA Stock slipped -0.27% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 50/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
GNTA — Genenta Science S.p.A.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:19:36Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, GNTA carries an RQD Score of 50 out of 100, a letter grade of D, and the verdict label "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the Fundamental Cash Engine scores 12 out of 20, reflecting an ROIC of 0% and an FCF yield of 0%. The Whale 13F Flow pillar scores 7 out of 20 on institutional accumulation and options positioning. The Insider Conviction pillar scores 9 out of 20 on SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 9 out of 20, with a Beta of 1.0 and a sector-sensitivity read. The Forensic Balance Sheet pillar scores 13 out of 20, citing an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.
For a prospective investor evaluating the stock today, the upside drivers are limited in the source data: the forensic balance-sheet pillar is the strongest component, while the zero-percent ROIC and FCF yield leave little cash-generation support for the valuation. Valuation tradeoffs cannot be assessed on earnings multiples because P/E and EV/EBITDA are not available in source data. The weakest pillars (institutional flow and insider conviction) indicate that the source data does not show strong accumulation signals. This brief is analytical and educational, not personalized financial advice.
Business
Genenta Science S.p.A. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, it is classified within this industry with a market capitalization of $0.0B. Not available in source data: product lines, customer base, and revenue model.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the most prominent items concern a Nasdaq minimum bid price deficiency notice, reported on two separate occasions. Per the news feed, the company has also adopted the Saentra Forge business name, with one headline noting that shareholders need take no action. The feed further includes a stock price prediction article. All items are tagged as YELLOW with a MARKET WIRE impact label.
Risk watch items: the Nasdaq minimum bid price deficiency notices are the most direct listing-compliance catalysts in the source data. The stock's trading price of 0.62 and 52-week range of $0.55 - $2.93 sit near the low end of that range. Per the Butterfly Supply-Chain Graph, there are no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies are therefore not available in source data. Sector correlations beyond the Health Care sector classification are not available in source data. Second-order bottlenecks are not available in source data.
Open Questions
- What revenue, operating income, and cash flow have been reported in recent periods, given that margins and FCF yield are shown as 0%?
- What is the current status and timeline for resolving the Nasdaq minimum bid price deficiency, and what remediation options are disclosed?
- What is the underlying business and product pipeline behind the Saentra Forge name change?
- What is the composition of institutional (13F) and insider (Form 4) ownership, given that holder data is not available?
- What analyst coverage and price targets exist for the stock, given that analyst data is not available?
GNTA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Genenta Science S.p.A. (GNTA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 10h ago
Genenta Science S.p.A. Estimates – NASDAQ:GNTA TradingView report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 13h ago
Shareholders need no action as Genenta adopts the Saentra Forge name Stock Titan report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 16h ago
Genenta Science receives Nasdaq minimum bid price deficiency notice TradingView report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 19h ago
A new business name, not a legal-name change: Genenta Science (Nasdaq: GNTA) will use Saentra Forge. Stock Titan report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Manila Times • 22h ago
Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification The Manila Times report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Genenta Science S.p.A. ADR (GNTA) Stock Price Prediction for 2026, 2030-2040 Traders Union report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Genenta Science S.p.A. ADR Stock Price Today | GNTA Live Chart & News Traders Union report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TipRanks • 1d ago
Genenta Science Faces Nasdaq Minimum Bid Price Deficiency, Explores Options to Preserve Listing TipRanks report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
GNTA Bull vs. Bear Conversation Board — What's Your Call at $0.62?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GNTA 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $0.67 (+8.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is GNTA (D • RQD 50/100) a Buy at $0.62?
Welcome to the GNTA (Genenta Science S.p.A.) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.47 (-24.2%)
Spot @ $0.62 Pump the brakes on GNTA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on GNTA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Genenta Science S.p.A. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $0.79 (+27.4%)
Spot @ $0.62 GNTA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on GNTA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.62 (52-wk range $0.55 - $2.93), any beat on forward guidance forces shorts and underweight funds to chase.